 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || AZD3427 / AstraZeneca
Enrollment open: Re-PERFUSE: AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment (clinicaltrials.gov) - Nov 12, 2024
P1, N=12, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting
- || AZD3427 / AstraZeneca
New P1 trial: Re-PERFUSE: AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment (clinicaltrials.gov) - Sep 25, 2024
P1, N=12, Not yet recruiting, Sponsor: AstraZeneca
- AZD3427 / AstraZeneca
AZD3427, a relaxin mimetic in pulmonary hypertension group 2 associated with left heart disease: design and rationale of the phase 2b Re-PHIRE Study (ePosters screen 11) - Mar 4, 2024 - Abstract #HEARTFAILURE2024HEART_FAILURE_1965;
Re-PHIRE is the first study of a relaxin mimetic in PH-LHD. Insights gained from this study are expected to inform the further development of AZD3427 in the PH-LHD population.
- | AZD3427 / AstraZeneca
Phase classification: Re-PHIRE: A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 (clinicaltrials.gov) - Nov 27, 2023
P2, N=220, Recruiting, Sponsor: AstraZeneca
Insights gained from this study are expected to inform the further development of AZD3427 in the PH-LHD population. Phase classification: P2b --> P2
- |||| AZD3427 / AstraZeneca
Enrollment open: Re-PHIRE: A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 (clinicaltrials.gov) - May 6, 2023
P2b, N=220, Recruiting, Sponsor: AstraZeneca
Phase classification: P2b --> P2 Not yet recruiting --> Recruiting
- AZD3427 / AstraZeneca
Safety, pharmacokinetics, and pharmacodynamics of AZD3427, a functionally selective long acting relaxin mimetic agonist of the RXFP1 receptor (Moderated ePosters 3) - Feb 28, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_767;
AZD3427 was generally well tolerated. These findings support further evaluation of AZD3427 in patients with HF.
- |||||| AZD3427 / AstraZeneca
New P2b trial: Re-PHIRE: A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 (clinicaltrials.gov) - Feb 21, 2023
P2b, N=220, Not yet recruiting, Sponsor: AstraZeneca
- ||| AZD3427 / AstraZeneca
Trial completion: Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427 (clinicaltrials.gov) - Oct 20, 2022
P1, N=105, Completed, Sponsor: AstraZeneca
These findings support further evaluation of AZD3427 in patients with HF. Active, not recruiting --> Completed
- || AZD3427 / AstraZeneca
Enrollment closed: Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427 (clinicaltrials.gov) - Aug 22, 2022
P1, N=105, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || AZD3427 / AstraZeneca
Trial completion date, Trial primary completion date: Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427 (clinicaltrials.gov) - Mar 31, 2022
P1, N=104, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: May 2022 --> Aug 2022
- | AZD3427 / AstraZeneca
Enrollment change, Trial withdrawal: Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure (clinicaltrials.gov) - Dec 17, 2021
P1, N=0, Withdrawn, Sponsor: AstraZeneca
Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: May 2022 --> Aug 2022 N=16 --> 0 | Not yet recruiting --> Withdrawn
- | AZD3427 / AstraZeneca
Trial completion date, Trial primary completion date: Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure (clinicaltrials.gov) - Oct 21, 2021
P1, N=16, Not yet recruiting, Sponsor: AstraZeneca
N=16 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2022 --> Aug 2022
- || AZD3427 / AstraZeneca
Trial completion date, Trial primary completion date: Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427 (clinicaltrials.gov) - Aug 19, 2021
P1, N=104, Recruiting, Sponsor: AstraZeneca
Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2022 --> Aug 2022 Trial completion date: Oct 2021 --> May 2022 | Trial primary completion date: Oct 2021 --> May 2022
- || AZD3427 / AstraZeneca
Trial completion date, Trial initiation date, Trial primary completion date: Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure (clinicaltrials.gov) - Jul 20, 2021
P1, N=16, Not yet recruiting, Sponsor: AstraZeneca
Trial completion date: Oct 2021 --> May 2022 | Trial primary completion date: Oct 2021 --> May 2022 Trial completion date: Nov 2021 --> Mar 2022 | Initiation date: Jun 2021 --> Oct 2021 | Trial primary completion date: Nov 2021 --> Mar 2022
- || AZD3427 / AstraZeneca
New P1 trial: Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure (clinicaltrials.gov) - May 17, 2021
P1, N=16, Not yet recruiting, Sponsor: AstraZeneca
- ||| AZD3427 / AstraZeneca
Enrollment open: Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427 (clinicaltrials.gov) - Nov 29, 2020
P1, N=104, Recruiting, Sponsor: AstraZeneca
Trial completion date: Nov 2021 --> Mar 2022 | Initiation date: Jun 2021 --> Oct 2021 | Trial primary completion date: Nov 2021 --> Mar 2022 Not yet recruiting --> Recruiting
- ||| AZD3427 / AstraZeneca
New P1 trial: Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427 (clinicaltrials.gov) - Nov 15, 2020
P1, N=104, Not yet recruiting, Sponsor: AstraZeneca